23776-98-9

Basic information

• Product Name: (4-ACETYLAMINO-BENZENESULFONYLAMINO)-ACETIC ACID
• Synonyms: N-4-AcetaMidophenylsulfonylglycine
• CAS NO: 23776-98-9
• Molecular Formula: C₁₀H₁₂N₂O₅S
• Molecular Weight: 272.28
• Mol File: 23776-98-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 230-232 °C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.477g/cm³
• PKA: 3.35±0.10(Predicted)
• CAS DataBase Reference: (4-ACETYLAMINO-BENZENESULFONYLAMINO)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (4-ACETYLAMINO-BENZENESULFONYLAMINO)-ACETIC ACID(23776-98-9)
• EPA Substance Registry System: (4-ACETYLAMINO-BENZENESULFONYLAMINO)-ACETIC ACID(23776-98-9)

Safety Data

• Hazardous Substances Data: 23776-98-9(Hazardous Substances Data)

Usage

Description

(4-ACETYLAMINO-BENZENESULFONYLAMINO)-ACETIC ACID, also known as N-4-Acetamidophenylsulfonylglycine, is an organic compound with a complex chemical structure. It is characterized by its benzene ring with an acetylamino and a benzenesulfonylamino group attached, as well as an acetic acid functional group. (4-ACETYLAMINO-BENZENESULFONYLAMINO)-ACETIC ACID serves as a versatile building block in the synthesis of various pharmaceuticals and bioactive molecules due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
(4-ACETYLAMINO-BENZENESULFONYLAMINO)-ACETIC ACID is used as a building block for the synthesis of (Aminophenylsulfonylaminomethyl)quinazolinone derivatives. These derivatives exhibit potent antibacterial and antifungal properties, making them valuable in the development of new drugs to combat resistant infections.
Used in Antimicrobial Applications:
As a reactant in the preparation of (Aminophenylsulfonylaminomethyl)quinazolinone derivatives, (4-ACETYLAMINO-BENZENESULFONYLAMINO)-ACETIC ACID contributes to the development of novel antimicrobial agents. These agents are particularly useful in addressing the growing issue of antibiotic resistance and the need for new treatments against fungal infections.

InChI:InChI=1/C10H12N2O5S/c1-7(13)12-8-2-4-9(5-3-8)18(16,17)11-6-10(14)15/h2-5,11H,6H2,1H3,(H,12,13)(H,14,15)/p-1

Upstream product

• 79-11-8 chloroacetic acid 
• 121-61-9 p-acetylaminobenzenesulfonamide 
• 56-40-6 glycine 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 
• 103-84-4 Acetanilid 

Downstream Products

• 99170-71-5 N-sulfanilyl-glycine ethyl ester 
• 99362-95-5 methyl 2-(4-aminophenylsulfonamido)acetate 
• 5616-30-8 2-(4-aminobenzenesulfonylamino)ethanoic acid 
• 858252-76-3 N-(4-amino-3,5-diiodo-benzenesulfonyl)-glycine 
• 100255-02-5 N-(N-acetyl-sulfanilyl)-glycine ethyl ester 
• 83800-75-3 N-[4-(4-Oxo-2-thioxo-imidazolidine-1-sulfonyl)-phenyl]-acetamide 
• 117163-91-4 N-sulfanilyl-glycine dimethylamide 
• 55578-35-3 N-(N-sulfanilyl-sulfanilyl)-glycine 
• 95983-14-5 N-sulfanilyl-glycine butylamide 
• 92503-84-9 N-sulfanilyl-glycine amide 
• 121-61-9 p-acetylaminobenzenesulfonamide 

Relevant articles and documents

Design, synthesis and in vitro evaluation studies of sulfonyl-amino-acetamides as small molecule BACE-1 inhibitors

The identification of a series of sulfonyl-amino-acetamides as BACE-1 (β-secretase) inhibitors for the treatment of Alzheimer's disease is reported. The derivatives were designed based on the docking simulation study, synthesized and assessed for BACE-1 inhibition in vitro. The designed ligands revealed desired binding interactions with the catalytic aspartate dyad and occupance of S1 and S2′ active site regions. These in silico results correlated well with in vitro activity. Out of 33 compounds synthesized, 12 compounds showed significant inhibition at 10 μM concentration. The most active compound 2.17S had IC50 of 7.90 μM against BACE-1, which was concomitant with results of in silico docking study.

Sulfonylamino acid derivatives

The present invention is related to: (i) matrix metalloproteinase inhibitors containing sulfonylamino acid derivatives of the formula (Ia): wherein R1is hydrogen, C1-4 alkyl; R is hydrogen, C1-8 alkyl etc.; E is —CONR3—, in which R3is hydrogen, C1-4 alkyl etc., —NR3CO—, —CO—O—, —O—CO— etc.; A is hydrogen, C1-8 alkyl, C3-7 cycloalkyl, or Ar; J is bond, C2-4 alkylene etc.; G is —(CH2)m— in which m is 2, 3 or 4, or in which R6and R7is hydrogen, C1-8 alkyl etc.; and non-toxic salts thereof, (ii) novel sulfonylamino acid derivatives of the formula (Ib): wherein all the symbols are the same meaning as (i); and non-toxic salts thereof, and (iii) process for the preparation of the compound of the formula (Ib). The compounds of the formula (Ia) are useful for prevention and/or treatment of diseases induced by overexpression and excess activity of MMP. The diseases such as above, for example, are rheumatoid, arthrosteitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cell, autoimmune disease (Crohn's disease, Sjogren's syndrome etc.), disease caused by vascular emigration or infiltration of leukocytes, arterialization.

Novel inhibitors of rat lens aldose reductase: N-[[(substituted amino)phenyl]sulfonyl]glycines

-